nodes	percent_of_prediction	percent_of_DWPC	metapath
Vismodegib—Sorafenib—thyroid cancer	0.714	1	CrCtD
Vismodegib—ORM1—Vandetanib—thyroid cancer	0.0553	0.278	CbGbCtD
Vismodegib—ABCG2—Vandetanib—thyroid cancer	0.0337	0.17	CbGbCtD
Vismodegib—ALB—Vandetanib—thyroid cancer	0.0233	0.117	CbGbCtD
Vismodegib—ABCG2—Sorafenib—thyroid cancer	0.0203	0.102	CbGbCtD
Vismodegib—ABCG2—Doxorubicin—thyroid cancer	0.0123	0.0621	CbGbCtD
Vismodegib—CYP2C8—Sorafenib—thyroid cancer	0.0108	0.0546	CbGbCtD
Vismodegib—CYP2C19—Sorafenib—thyroid cancer	0.00909	0.0458	CbGbCtD
Vismodegib—CYP2C9—Sorafenib—thyroid cancer	0.00755	0.0381	CbGbCtD
Vismodegib—ABCB1—Sorafenib—thyroid cancer	0.00733	0.0369	CbGbCtD
Vismodegib—CYP3A4—Vandetanib—thyroid cancer	0.00729	0.0367	CbGbCtD
Vismodegib—ABCB1—Doxorubicin—thyroid cancer	0.00445	0.0224	CbGbCtD
Vismodegib—CYP3A4—Sorafenib—thyroid cancer	0.00439	0.0221	CbGbCtD
Vismodegib—Potassium low—Vandetanib—thyroid cancer	0.00435	0.101	CcSEcCtD
Vismodegib—Potassium low—Sorafenib—thyroid cancer	0.00293	0.0685	CcSEcCtD
Vismodegib—CYP3A4—Doxorubicin—thyroid cancer	0.00267	0.0134	CbGbCtD
Vismodegib—Musculoskeletal disorder—Vandetanib—thyroid cancer	0.00255	0.0595	CcSEcCtD
Vismodegib—Blood potassium decreased—Vandetanib—thyroid cancer	0.0024	0.0559	CcSEcCtD
Vismodegib—Blood potassium decreased—Sorafenib—thyroid cancer	0.00162	0.0377	CcSEcCtD
Vismodegib—Sorafenib—RET—thyroid cancer	0.00107	0.428	CrCbGaD
Vismodegib—Neoplasm malignant—Sorafenib—thyroid cancer	0.00072	0.0168	CcSEcCtD
Vismodegib—Hyponatraemia—Vandetanib—thyroid cancer	0.000664	0.0155	CcSEcCtD
Vismodegib—Sorafenib—BRAF—thyroid cancer	0.00066	0.264	CrCbGaD
Vismodegib—Dehydration—Vandetanib—thyroid cancer	0.000615	0.0144	CcSEcCtD
Vismodegib—Hypokalaemia—Vandetanib—thyroid cancer	0.000602	0.014	CcSEcCtD
Vismodegib—Musculoskeletal chest pain—Epirubicin—thyroid cancer	0.000586	0.0137	CcSEcCtD
Vismodegib—Musculoskeletal chest pain—Doxorubicin—thyroid cancer	0.000542	0.0127	CcSEcCtD
Vismodegib—Weight decreased—Vandetanib—thyroid cancer	0.000517	0.0121	CcSEcCtD
Vismodegib—Hyponatraemia—Sorafenib—thyroid cancer	0.000448	0.0105	CcSEcCtD
Vismodegib—Pain in extremity—Sorafenib—thyroid cancer	0.000446	0.0104	CcSEcCtD
Vismodegib—Dehydration—Sorafenib—thyroid cancer	0.000415	0.00968	CcSEcCtD
Vismodegib—Abdominal pain upper—Sorafenib—thyroid cancer	0.000407	0.00951	CcSEcCtD
Vismodegib—Hypokalaemia—Sorafenib—thyroid cancer	0.000406	0.00948	CcSEcCtD
Vismodegib—Alopecia—Vandetanib—thyroid cancer	0.000404	0.00944	CcSEcCtD
Vismodegib—Breast disorder—Sorafenib—thyroid cancer	0.000403	0.00941	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Sorafenib—thyroid cancer	0.000402	0.00938	CcSEcCtD
Vismodegib—Malnutrition—Vandetanib—thyroid cancer	0.000398	0.0093	CcSEcCtD
Vismodegib—Dysgeusia—Vandetanib—thyroid cancer	0.00039	0.0091	CcSEcCtD
Vismodegib—Muscle spasms—Vandetanib—thyroid cancer	0.000383	0.00894	CcSEcCtD
Vismodegib—Sulfasalazine—PPARG—thyroid cancer	0.00036	0.144	CrCbGaD
Vismodegib—SMO—saliva-secreting gland—thyroid cancer	0.00036	0.192	CbGeAlD
Vismodegib—Weight decreased—Sorafenib—thyroid cancer	0.000349	0.00814	CcSEcCtD
Vismodegib—Arthralgia—Vandetanib—thyroid cancer	0.000339	0.00791	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.000337	0.00786	CcSEcCtD
Vismodegib—Nervous system disorder—Vandetanib—thyroid cancer	0.000319	0.00744	CcSEcCtD
Vismodegib—Skin disorder—Vandetanib—thyroid cancer	0.000316	0.00737	CcSEcCtD
Vismodegib—Connective tissue disorder—Sorafenib—thyroid cancer	0.000303	0.00708	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.000296	0.00691	CcSEcCtD
Vismodegib—Dyspepsia—Vandetanib—thyroid cancer	0.000286	0.00668	CcSEcCtD
Vismodegib—Decreased appetite—Vandetanib—thyroid cancer	0.000283	0.0066	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.000281	0.00655	CcSEcCtD
Vismodegib—Ageusia—Epirubicin—thyroid cancer	0.00028	0.00654	CcSEcCtD
Vismodegib—Fatigue—Vandetanib—thyroid cancer	0.00028	0.00654	CcSEcCtD
Vismodegib—SHH—head—thyroid cancer	0.000279	0.149	CbGeAlD
Vismodegib—Constipation—Vandetanib—thyroid cancer	0.000278	0.00649	CcSEcCtD
Vismodegib—Pain—Vandetanib—thyroid cancer	0.000278	0.00649	CcSEcCtD
Vismodegib—SMO—trachea—thyroid cancer	0.000278	0.148	CbGeAlD
Vismodegib—Alopecia—Sorafenib—thyroid cancer	0.000273	0.00637	CcSEcCtD
Vismodegib—Malnutrition—Sorafenib—thyroid cancer	0.000269	0.00627	CcSEcCtD
Vismodegib—Neoplasm malignant—Epirubicin—thyroid cancer	0.000266	0.00621	CcSEcCtD
Vismodegib—Gastrointestinal pain—Vandetanib—thyroid cancer	0.000266	0.0062	CcSEcCtD
Vismodegib—Dysgeusia—Sorafenib—thyroid cancer	0.000263	0.00614	CcSEcCtD
Vismodegib—Ageusia—Doxorubicin—thyroid cancer	0.000259	0.00605	CcSEcCtD
Vismodegib—Amenorrhoea—Epirubicin—thyroid cancer	0.000259	0.00603	CcSEcCtD
Vismodegib—Muscle spasms—Sorafenib—thyroid cancer	0.000258	0.00603	CcSEcCtD
Vismodegib—Etoricoxib—PTGS2—thyroid cancer	0.000258	0.103	CrCbGaD
Vismodegib—Abdominal pain—Vandetanib—thyroid cancer	0.000257	0.006	CcSEcCtD
Vismodegib—Neoplasm malignant—Doxorubicin—thyroid cancer	0.000246	0.00574	CcSEcCtD
Vismodegib—Amenorrhoea—Doxorubicin—thyroid cancer	0.000239	0.00558	CcSEcCtD
Vismodegib—Asthenia—Vandetanib—thyroid cancer	0.000233	0.00544	CcSEcCtD
Vismodegib—Pruritus—Vandetanib—thyroid cancer	0.00023	0.00537	CcSEcCtD
Vismodegib—Musculoskeletal pain—Epirubicin—thyroid cancer	0.00023	0.00537	CcSEcCtD
Vismodegib—Myalgia—Sorafenib—thyroid cancer	0.000229	0.00534	CcSEcCtD
Vismodegib—Arthralgia—Sorafenib—thyroid cancer	0.000229	0.00534	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.000227	0.0053	CcSEcCtD
Vismodegib—Phosphatase alkaline increased—Epirubicin—thyroid cancer	0.000227	0.0053	CcSEcCtD
Vismodegib—Diarrhoea—Vandetanib—thyroid cancer	0.000222	0.00519	CcSEcCtD
Vismodegib—SMO—thyroid gland—thyroid cancer	0.00022	0.117	CbGeAlD
Vismodegib—Nervous system disorder—Sorafenib—thyroid cancer	0.000215	0.00502	CcSEcCtD
Vismodegib—Blood urea increased—Epirubicin—thyroid cancer	0.000214	0.00501	CcSEcCtD
Vismodegib—Skin disorder—Sorafenib—thyroid cancer	0.000213	0.00497	CcSEcCtD
Vismodegib—Musculoskeletal pain—Doxorubicin—thyroid cancer	0.000213	0.00496	CcSEcCtD
Vismodegib—Phosphatase alkaline increased—Doxorubicin—thyroid cancer	0.00021	0.00491	CcSEcCtD
Vismodegib—Vomiting—Vandetanib—thyroid cancer	0.000207	0.00482	CcSEcCtD
Vismodegib—Rash—Vandetanib—thyroid cancer	0.000205	0.00478	CcSEcCtD
Vismodegib—Dermatitis—Vandetanib—thyroid cancer	0.000205	0.00478	CcSEcCtD
Vismodegib—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.0002	0.00466	CcSEcCtD
Vismodegib—Blood urea increased—Doxorubicin—thyroid cancer	0.000198	0.00463	CcSEcCtD
Vismodegib—SMO—head—thyroid cancer	0.000195	0.104	CbGeAlD
Vismodegib—Nausea—Vandetanib—thyroid cancer	0.000193	0.00451	CcSEcCtD
Vismodegib—Dyspepsia—Sorafenib—thyroid cancer	0.000193	0.00451	CcSEcCtD
Vismodegib—Decreased appetite—Sorafenib—thyroid cancer	0.000191	0.00445	CcSEcCtD
Vismodegib—Blood alkaline phosphatase increased—Epirubicin—thyroid cancer	0.00019	0.00442	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000189	0.00442	CcSEcCtD
Vismodegib—Fatigue—Sorafenib—thyroid cancer	0.000189	0.00441	CcSEcCtD
Vismodegib—Pain—Sorafenib—thyroid cancer	0.000188	0.00438	CcSEcCtD
Vismodegib—Constipation—Sorafenib—thyroid cancer	0.000188	0.00438	CcSEcCtD
Vismodegib—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000179	0.00419	CcSEcCtD
Vismodegib—Blood alkaline phosphatase increased—Doxorubicin—thyroid cancer	0.000175	0.00409	CcSEcCtD
Vismodegib—Abdominal pain—Sorafenib—thyroid cancer	0.000173	0.00405	CcSEcCtD
Vismodegib—Hyponatraemia—Epirubicin—thyroid cancer	0.000166	0.00386	CcSEcCtD
Vismodegib—Pain in extremity—Epirubicin—thyroid cancer	0.000165	0.00385	CcSEcCtD
Vismodegib—Asthenia—Sorafenib—thyroid cancer	0.000157	0.00367	CcSEcCtD
Vismodegib—Pruritus—Sorafenib—thyroid cancer	0.000155	0.00362	CcSEcCtD
Vismodegib—Dehydration—Epirubicin—thyroid cancer	0.000153	0.00358	CcSEcCtD
Vismodegib—Hyponatraemia—Doxorubicin—thyroid cancer	0.000153	0.00358	CcSEcCtD
Vismodegib—Pain in extremity—Doxorubicin—thyroid cancer	0.000153	0.00356	CcSEcCtD
Vismodegib—Sulfasalazine—PTGS2—thyroid cancer	0.000152	0.0609	CrCbGaD
Vismodegib—Abdominal pain upper—Epirubicin—thyroid cancer	0.000151	0.00351	CcSEcCtD
Vismodegib—Hypokalaemia—Epirubicin—thyroid cancer	0.00015	0.0035	CcSEcCtD
Vismodegib—Diarrhoea—Sorafenib—thyroid cancer	0.00015	0.0035	CcSEcCtD
Vismodegib—Breast disorder—Epirubicin—thyroid cancer	0.000149	0.00348	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.000148	0.00347	CcSEcCtD
Vismodegib—Dehydration—Doxorubicin—thyroid cancer	0.000142	0.00331	CcSEcCtD
Vismodegib—Vomiting—Sorafenib—thyroid cancer	0.000139	0.00325	CcSEcCtD
Vismodegib—Abdominal pain upper—Doxorubicin—thyroid cancer	0.000139	0.00325	CcSEcCtD
Vismodegib—Hypokalaemia—Doxorubicin—thyroid cancer	0.000139	0.00324	CcSEcCtD
Vismodegib—Rash—Sorafenib—thyroid cancer	0.000138	0.00323	CcSEcCtD
Vismodegib—Dermatitis—Sorafenib—thyroid cancer	0.000138	0.00322	CcSEcCtD
Vismodegib—Breast disorder—Doxorubicin—thyroid cancer	0.000138	0.00322	CcSEcCtD
Vismodegib—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.000137	0.00321	CcSEcCtD
Vismodegib—SMO—lymph node—thyroid cancer	0.000137	0.0728	CbGeAlD
Vismodegib—Nausea—Sorafenib—thyroid cancer	0.00013	0.00304	CcSEcCtD
Vismodegib—Weight decreased—Epirubicin—thyroid cancer	0.000129	0.00301	CcSEcCtD
Vismodegib—Weight decreased—Doxorubicin—thyroid cancer	0.000119	0.00278	CcSEcCtD
Vismodegib—Connective tissue disorder—Epirubicin—thyroid cancer	0.000112	0.00262	CcSEcCtD
Vismodegib—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000104	0.00242	CcSEcCtD
Vismodegib—Alopecia—Epirubicin—thyroid cancer	0.000101	0.00235	CcSEcCtD
Vismodegib—Malnutrition—Epirubicin—thyroid cancer	9.93e-05	0.00232	CcSEcCtD
Vismodegib—Dysgeusia—Epirubicin—thyroid cancer	9.72e-05	0.00227	CcSEcCtD
Vismodegib—Back pain—Epirubicin—thyroid cancer	9.6e-05	0.00224	CcSEcCtD
Vismodegib—Muscle spasms—Epirubicin—thyroid cancer	9.55e-05	0.00223	CcSEcCtD
Vismodegib—ABCG2—saliva-secreting gland—thyroid cancer	9.43e-05	0.0503	CbGeAlD
Vismodegib—Alopecia—Doxorubicin—thyroid cancer	9.33e-05	0.00218	CcSEcCtD
Vismodegib—Malnutrition—Doxorubicin—thyroid cancer	9.19e-05	0.00214	CcSEcCtD
Vismodegib—Dysgeusia—Doxorubicin—thyroid cancer	9e-05	0.0021	CcSEcCtD
Vismodegib—Back pain—Doxorubicin—thyroid cancer	8.89e-05	0.00207	CcSEcCtD
Vismodegib—Muscle spasms—Doxorubicin—thyroid cancer	8.83e-05	0.00206	CcSEcCtD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	8.46e-05	0.00212	CbGpPWpGaD
Vismodegib—Arthralgia—Epirubicin—thyroid cancer	8.45e-05	0.00197	CcSEcCtD
Vismodegib—Myalgia—Epirubicin—thyroid cancer	8.45e-05	0.00197	CcSEcCtD
Vismodegib—ABCG2—HIF-1-alpha transcription factor network—TERT—thyroid cancer	8.45e-05	0.00211	CbGpPWpGaD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	8.4e-05	0.00196	CcSEcCtD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	8.31e-05	0.00208	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—TSHR—thyroid cancer	8.18e-05	0.00205	CbGpPWpGaD
Vismodegib—ABCG2—HIF-1-alpha transcription factor network—HIF1A—thyroid cancer	8.08e-05	0.00202	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—PRKAR1A—thyroid cancer	8.04e-05	0.00201	CbGpPWpGaD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	8.02e-05	0.00201	CbGpPWpGaD
Vismodegib—Nervous system disorder—Epirubicin—thyroid cancer	7.95e-05	0.00185	CcSEcCtD
Vismodegib—Skin disorder—Epirubicin—thyroid cancer	7.87e-05	0.00184	CcSEcCtD
Vismodegib—Arthralgia—Doxorubicin—thyroid cancer	7.82e-05	0.00183	CcSEcCtD
Vismodegib—Myalgia—Doxorubicin—thyroid cancer	7.82e-05	0.00183	CcSEcCtD
Vismodegib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	7.77e-05	0.00181	CcSEcCtD
Vismodegib—SMO—Signaling by GPCR—TSHR—thyroid cancer	7.75e-05	0.00194	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—PRKAR1A—thyroid cancer	7.63e-05	0.00191	CbGpPWpGaD
Vismodegib—Musculoskeletal discomfort—Epirubicin—thyroid cancer	7.38e-05	0.00172	CcSEcCtD
Vismodegib—Nervous system disorder—Doxorubicin—thyroid cancer	7.35e-05	0.00172	CcSEcCtD
Vismodegib—ABCB1—HIF-1-alpha transcription factor network—EPO—thyroid cancer	7.34e-05	0.00184	CbGpPWpGaD
Vismodegib—CYP2C8—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	7.29e-05	0.00182	CbGpPWpGaD
Vismodegib—Skin disorder—Doxorubicin—thyroid cancer	7.28e-05	0.0017	CcSEcCtD
Vismodegib—Dyspepsia—Epirubicin—thyroid cancer	7.13e-05	0.00166	CcSEcCtD
Vismodegib—Decreased appetite—Epirubicin—thyroid cancer	7.04e-05	0.00164	CcSEcCtD
Vismodegib—Gastrointestinal disorder—Epirubicin—thyroid cancer	7e-05	0.00163	CcSEcCtD
Vismodegib—Fatigue—Epirubicin—thyroid cancer	6.99e-05	0.00163	CcSEcCtD
Vismodegib—SHH—Signaling by GPCR—PTCH1—thyroid cancer	6.95e-05	0.00174	CbGpPWpGaD
Vismodegib—Constipation—Epirubicin—thyroid cancer	6.93e-05	0.00162	CcSEcCtD
Vismodegib—Pain—Epirubicin—thyroid cancer	6.93e-05	0.00162	CcSEcCtD
Vismodegib—SHH—Disease—TPR—thyroid cancer	6.9e-05	0.00173	CbGpPWpGaD
Vismodegib—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	6.83e-05	0.00159	CcSEcCtD
Vismodegib—SHH—Disease—PRKAR1A—thyroid cancer	6.79e-05	0.0017	CbGpPWpGaD
Vismodegib—Gastrointestinal pain—Epirubicin—thyroid cancer	6.63e-05	0.00155	CcSEcCtD
Vismodegib—Dyspepsia—Doxorubicin—thyroid cancer	6.6e-05	0.00154	CcSEcCtD
Vismodegib—SHH—Signaling Pathways—TCF7L1—thyroid cancer	6.6e-05	0.00165	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—PTCH1—thyroid cancer	6.59e-05	0.00165	CbGpPWpGaD
Vismodegib—Decreased appetite—Doxorubicin—thyroid cancer	6.52e-05	0.00152	CcSEcCtD
Vismodegib—CYP2C19—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	6.5e-05	0.00163	CbGpPWpGaD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	6.5e-05	0.00163	CbGpPWpGaD
Vismodegib—SHH—Disease—MEN1—thyroid cancer	6.49e-05	0.00162	CbGpPWpGaD
Vismodegib—Gastrointestinal disorder—Doxorubicin—thyroid cancer	6.47e-05	0.00151	CcSEcCtD
Vismodegib—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	6.47e-05	0.00162	CbGpPWpGaD
Vismodegib—Fatigue—Doxorubicin—thyroid cancer	6.46e-05	0.00151	CcSEcCtD
Vismodegib—Constipation—Doxorubicin—thyroid cancer	6.41e-05	0.0015	CcSEcCtD
Vismodegib—Pain—Doxorubicin—thyroid cancer	6.41e-05	0.0015	CcSEcCtD
Vismodegib—Abdominal pain—Epirubicin—thyroid cancer	6.41e-05	0.0015	CcSEcCtD
Vismodegib—SHH—Signaling by GPCR—SST—thyroid cancer	6.36e-05	0.00159	CbGpPWpGaD
Vismodegib—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	6.31e-05	0.00158	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—TCF7L1—thyroid cancer	6.26e-05	0.00156	CbGpPWpGaD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	6.16e-05	0.00154	CbGpPWpGaD
Vismodegib—Gastrointestinal pain—Doxorubicin—thyroid cancer	6.13e-05	0.00143	CcSEcCtD
Vismodegib—SHH—Signaling by GPCR—CALCA—thyroid cancer	6.12e-05	0.00153	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—SST—thyroid cancer	6.03e-05	0.00151	CbGpPWpGaD
Vismodegib—ORM1—lymph node—thyroid cancer	5.97e-05	0.0318	CbGeAlD
Vismodegib—CYP2C9—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	5.93e-05	0.00148	CbGpPWpGaD
Vismodegib—Abdominal pain—Doxorubicin—thyroid cancer	5.93e-05	0.00138	CcSEcCtD
Vismodegib—CYP2C8—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	5.91e-05	0.00148	CbGpPWpGaD
Vismodegib—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	5.9e-05	0.00148	CbGpPWpGaD
Vismodegib—Asthenia—Epirubicin—thyroid cancer	5.81e-05	0.00136	CcSEcCtD
Vismodegib—SMO—Signaling by GPCR—CALCA—thyroid cancer	5.8e-05	0.00145	CbGpPWpGaD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	5.78e-05	0.00144	CbGpPWpGaD
Vismodegib—ABCG2—thyroid gland—thyroid cancer	5.76e-05	0.0307	CbGeAlD
Vismodegib—Pruritus—Epirubicin—thyroid cancer	5.73e-05	0.00134	CcSEcCtD
Vismodegib—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	5.7e-05	0.00143	CbGpPWpGaD
Vismodegib—ABCG2—Fluoropyrimidine Activity—TP53—thyroid cancer	5.6e-05	0.0014	CbGpPWpGaD
Vismodegib—Diarrhoea—Epirubicin—thyroid cancer	5.54e-05	0.00129	CcSEcCtD
Vismodegib—SHH—Signaling by GPCR—CDK1—thyroid cancer	5.54e-05	0.00139	CbGpPWpGaD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	5.48e-05	0.00137	CbGpPWpGaD
Vismodegib—Asthenia—Doxorubicin—thyroid cancer	5.38e-05	0.00126	CcSEcCtD
Vismodegib—Pruritus—Doxorubicin—thyroid cancer	5.3e-05	0.00124	CcSEcCtD
Vismodegib—CYP2C19—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	5.27e-05	0.00132	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—CDK1—thyroid cancer	5.25e-05	0.00131	CbGpPWpGaD
Vismodegib—ALB—lymph node—thyroid cancer	5.23e-05	0.0279	CbGeAlD
Vismodegib—SHH—Disease—CALCA—thyroid cancer	5.16e-05	0.00129	CbGpPWpGaD
Vismodegib—Vomiting—Epirubicin—thyroid cancer	5.15e-05	0.0012	CcSEcCtD
Vismodegib—Diarrhoea—Doxorubicin—thyroid cancer	5.13e-05	0.0012	CcSEcCtD
Vismodegib—Rash—Epirubicin—thyroid cancer	5.11e-05	0.00119	CcSEcCtD
Vismodegib—Dermatitis—Epirubicin—thyroid cancer	5.1e-05	0.00119	CcSEcCtD
Vismodegib—SHH—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	4.88e-05	0.00122	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—TSHR—thyroid cancer	4.83e-05	0.00121	CbGpPWpGaD
Vismodegib—Nausea—Epirubicin—thyroid cancer	4.81e-05	0.00112	CcSEcCtD
Vismodegib—CYP2C9—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	4.81e-05	0.0012	CbGpPWpGaD
Vismodegib—Vomiting—Doxorubicin—thyroid cancer	4.77e-05	0.00111	CcSEcCtD
Vismodegib—SHH—Signaling Pathways—PRKAR1A—thyroid cancer	4.75e-05	0.00119	CbGpPWpGaD
Vismodegib—Rash—Doxorubicin—thyroid cancer	4.73e-05	0.0011	CcSEcCtD
Vismodegib—Dermatitis—Doxorubicin—thyroid cancer	4.72e-05	0.0011	CcSEcCtD
Vismodegib—SHH—Disease—CDK1—thyroid cancer	4.67e-05	0.00117	CbGpPWpGaD
Vismodegib—SMO—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	4.62e-05	0.00116	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—TSHR—thyroid cancer	4.58e-05	0.00115	CbGpPWpGaD
Vismodegib—ABCB1—HIF-1-alpha transcription factor network—TERT—thyroid cancer	4.57e-05	0.00114	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—MEN1—thyroid cancer	4.54e-05	0.00114	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—PRKAR1A—thyroid cancer	4.5e-05	0.00113	CbGpPWpGaD
Vismodegib—Nausea—Doxorubicin—thyroid cancer	4.45e-05	0.00104	CcSEcCtD
Vismodegib—ABCB1—HIF-1-alpha transcription factor network—HIF1A—thyroid cancer	4.37e-05	0.00109	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—MEN1—thyroid cancer	4.31e-05	0.00108	CbGpPWpGaD
Vismodegib—CYP2C8—Arachidonic acid metabolism—PTGS2—thyroid cancer	4.19e-05	0.00105	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—PTCH1—thyroid cancer	4.11e-05	0.00103	CbGpPWpGaD
Vismodegib—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	3.91e-05	0.000978	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—PTCH1—thyroid cancer	3.89e-05	0.000974	CbGpPWpGaD
Vismodegib—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	3.89e-05	0.000973	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—SST—thyroid cancer	3.76e-05	0.00094	CbGpPWpGaD
Vismodegib—SHH—Disease—NRG1—thyroid cancer	3.75e-05	0.000938	CbGpPWpGaD
Vismodegib—CYP2C19—Arachidonic acid metabolism—PTGS2—thyroid cancer	3.74e-05	0.000935	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—MINPP1—thyroid cancer	3.71e-05	0.000929	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CALCA—thyroid cancer	3.62e-05	0.000904	CbGpPWpGaD
Vismodegib—ABCB1—trachea—thyroid cancer	3.59e-05	0.0191	CbGeAlD
Vismodegib—ABCG2—lymph node—thyroid cancer	3.58e-05	0.0191	CbGeAlD
Vismodegib—ALB—SLC-mediated transmembrane transport—CP—thyroid cancer	3.56e-05	0.000891	CbGpPWpGaD
Vismodegib—ALB—SLC-mediated transmembrane transport—TPR—thyroid cancer	3.56e-05	0.000891	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—SST—thyroid cancer	3.56e-05	0.000891	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CALCA—thyroid cancer	3.43e-05	0.000857	CbGpPWpGaD
Vismodegib—CYP2C9—Arachidonic acid metabolism—PTGS2—thyroid cancer	3.41e-05	0.000852	CbGpPWpGaD
Vismodegib—SHH—Disease—TERT—thyroid cancer	3.37e-05	0.000843	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	3.34e-05	0.000834	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	3.32e-05	0.00083	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CDK1—thyroid cancer	3.27e-05	0.000819	CbGpPWpGaD
Vismodegib—SHH—Disease—HIF1A—thyroid cancer	3.22e-05	0.000806	CbGpPWpGaD
Vismodegib—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	3.17e-05	0.000793	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—NDUFA13—thyroid cancer	3.16e-05	0.00079	CbGpPWpGaD
Vismodegib—CYP2C8—Biological oxidations—RXRA—thyroid cancer	3.14e-05	0.000785	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CDK1—thyroid cancer	3.1e-05	0.000776	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	2.98e-05	0.000745	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—CHST14—thyroid cancer	2.97e-05	0.000743	CbGpPWpGaD
Vismodegib—ABCG2—Transmembrane transport of small molecules—CP—thyroid cancer	2.94e-05	0.000734	CbGpPWpGaD
Vismodegib—ABCG2—Transmembrane transport of small molecules—TPR—thyroid cancer	2.94e-05	0.000734	CbGpPWpGaD
Vismodegib—ABCG2—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	2.89e-05	0.000722	CbGpPWpGaD
Vismodegib—ABCB1—thyroid gland—thyroid cancer	2.84e-05	0.0151	CbGeAlD
Vismodegib—CYP2C19—Biological oxidations—RXRA—thyroid cancer	2.8e-05	0.000701	CbGpPWpGaD
Vismodegib—ABCG2—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	2.72e-05	0.000679	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	2.71e-05	0.000679	CbGpPWpGaD
Vismodegib—ALB—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	2.67e-05	0.000667	CbGpPWpGaD
Vismodegib—SHH—Disease—BRAF—thyroid cancer	2.67e-05	0.000667	CbGpPWpGaD
Vismodegib—ALB—Selenium Micronutrient Network—PTGS2—thyroid cancer	2.65e-05	0.000663	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—NRG1—thyroid cancer	2.63e-05	0.000657	CbGpPWpGaD
Vismodegib—CYP2C9—Biological oxidations—RXRA—thyroid cancer	2.55e-05	0.000639	CbGpPWpGaD
Vismodegib—ABCB1—head—thyroid cancer	2.52e-05	0.0134	CbGeAlD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	2.51e-05	0.000629	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—NRG1—thyroid cancer	2.49e-05	0.000623	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—HPGD—thyroid cancer	2.39e-05	0.000599	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—TERT—thyroid cancer	2.36e-05	0.00059	CbGpPWpGaD
Vismodegib—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—thyroid cancer	2.32e-05	0.00058	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—MINPP1—thyroid cancer	2.31e-05	0.000577	CbGpPWpGaD
Vismodegib—ALB—Metabolism—MINPP1—thyroid cancer	2.29e-05	0.000573	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—HIF1A—thyroid cancer	2.26e-05	0.000564	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—TERT—thyroid cancer	2.24e-05	0.000559	CbGpPWpGaD
Vismodegib—ABCG2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	2.2e-05	0.00055	CbGpPWpGaD
Vismodegib—SHH—Disease—PTGS2—thyroid cancer	2.15e-05	0.000539	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—HIF1A—thyroid cancer	2.14e-05	0.000535	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—PRKAR1A—thyroid cancer	2.06e-05	0.000515	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—MINPP1—thyroid cancer	2.06e-05	0.000515	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—MINPP1—thyroid cancer	2.01e-05	0.000502	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—NRAS—thyroid cancer	1.99e-05	0.000497	CbGpPWpGaD
Vismodegib—ALB—Folate Metabolism—TP53—thyroid cancer	1.98e-05	0.000496	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—NDUFA13—thyroid cancer	1.96e-05	0.00049	CbGpPWpGaD
Vismodegib—ALB—Metabolism—NDUFA13—thyroid cancer	1.95e-05	0.000487	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—NRAS—thyroid cancer	1.88e-05	0.000471	CbGpPWpGaD
Vismodegib—SHH—Disease—PTEN—thyroid cancer	1.88e-05	0.00047	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—MINPP1—thyroid cancer	1.88e-05	0.000469	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—BRAF—thyroid cancer	1.87e-05	0.000467	CbGpPWpGaD
Vismodegib—ABCG2—Transmembrane transport of small molecules—RXRA—thyroid cancer	1.85e-05	0.000462	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—CHST14—thyroid cancer	1.84e-05	0.000461	CbGpPWpGaD
Vismodegib—ALB—Metabolism—CHST14—thyroid cancer	1.83e-05	0.000458	CbGpPWpGaD
Vismodegib—ALB—Transmembrane transport of small molecules—TPR—thyroid cancer	1.81e-05	0.000453	CbGpPWpGaD
Vismodegib—ALB—Transmembrane transport of small molecules—CP—thyroid cancer	1.81e-05	0.000453	CbGpPWpGaD
Vismodegib—ALB—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	1.78e-05	0.000446	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—BRAF—thyroid cancer	1.77e-05	0.000443	CbGpPWpGaD
Vismodegib—ABCB1—lymph node—thyroid cancer	1.76e-05	0.0094	CbGeAlD
Vismodegib—CYP2C19—Metabolism—NDUFA13—thyroid cancer	1.75e-05	0.000438	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—KRAS—thyroid cancer	1.71e-05	0.000428	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—NDUFA13—thyroid cancer	1.71e-05	0.000427	CbGpPWpGaD
Vismodegib—CYP3A4—Biological oxidations—RXRA—thyroid cancer	1.68e-05	0.000421	CbGpPWpGaD
Vismodegib—SHH—Disease—NRAS—thyroid cancer	1.68e-05	0.000419	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—CHST14—thyroid cancer	1.64e-05	0.000411	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—KRAS—thyroid cancer	1.62e-05	0.000406	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—CHST14—thyroid cancer	1.61e-05	0.000402	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—NDUFA13—thyroid cancer	1.6e-05	0.000399	CbGpPWpGaD
Vismodegib—ABCB1—Transmembrane transport of small molecules—TPR—thyroid cancer	1.59e-05	0.000397	CbGpPWpGaD
Vismodegib—ABCB1—Transmembrane transport of small molecules—CP—thyroid cancer	1.59e-05	0.000397	CbGpPWpGaD
Vismodegib—ABCB1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	1.56e-05	0.00039	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—CHST14—thyroid cancer	1.5e-05	0.000375	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—HPGD—thyroid cancer	1.49e-05	0.000372	CbGpPWpGaD
Vismodegib—ALB—Metabolism—HPGD—thyroid cancer	1.48e-05	0.000369	CbGpPWpGaD
Vismodegib—ABCB1—HIF-1-alpha transcription factor network—AKT1—thyroid cancer	1.47e-05	0.000367	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—HRAS—thyroid cancer	1.45e-05	0.000364	CbGpPWpGaD
Vismodegib—SHH—Disease—KRAS—thyroid cancer	1.44e-05	0.000361	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—HRAS—thyroid cancer	1.38e-05	0.000345	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—TPR—thyroid cancer	1.37e-05	0.000344	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—IFNA2—thyroid cancer	1.36e-05	0.000341	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—CCND1—thyroid cancer	1.36e-05	0.000341	CbGpPWpGaD
Vismodegib—ALB—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	1.36e-05	0.000339	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PRKAR1A—thyroid cancer	1.35e-05	0.000338	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—HPGD—thyroid cancer	1.33e-05	0.000332	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—PTEN—thyroid cancer	1.32e-05	0.000329	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—HPGD—thyroid cancer	1.29e-05	0.000324	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—CCND1—thyroid cancer	1.29e-05	0.000323	CbGpPWpGaD
Vismodegib—SHH—Signaling by GPCR—AKT1—thyroid cancer	1.28e-05	0.000321	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—thyroid cancer	1.25e-05	0.000312	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—PTEN—thyroid cancer	1.25e-05	0.000312	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—MINPP1—thyroid cancer	1.24e-05	0.000309	CbGpPWpGaD
Vismodegib—SHH—Disease—HRAS—thyroid cancer	1.23e-05	0.000307	CbGpPWpGaD
Vismodegib—SMO—Signaling by GPCR—AKT1—thyroid cancer	1.22e-05	0.000304	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—HPGD—thyroid cancer	1.21e-05	0.000302	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	1.2e-05	0.000301	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	1.2e-05	0.0003	CbGpPWpGaD
Vismodegib—ABCB1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	1.19e-05	0.000297	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—NRAS—thyroid cancer	1.17e-05	0.000294	CbGpPWpGaD
Vismodegib—ALB—Transmembrane transport of small molecules—RXRA—thyroid cancer	1.14e-05	0.000285	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	1.13e-05	0.000282	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—NRAS—thyroid cancer	1.11e-05	0.000278	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	1.09e-05	0.000272	CbGpPWpGaD
Vismodegib—SHH—Disease—AKT1—thyroid cancer	1.08e-05	0.000271	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	1.08e-05	0.000269	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—NDUFA13—thyroid cancer	1.05e-05	0.000263	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—SLC5A5—thyroid cancer	1.03e-05	0.000257	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—KRAS—thyroid cancer	1.01e-05	0.000253	CbGpPWpGaD
Vismodegib—ABCB1—Transmembrane transport of small molecules—RXRA—thyroid cancer	9.98e-06	0.00025	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—CHST14—thyroid cancer	9.89e-06	0.000247	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	9.81e-06	0.000245	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—KRAS—thyroid cancer	9.58e-06	0.00024	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—TP53—thyroid cancer	8.98e-06	0.000225	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—RXRA—thyroid cancer	8.65e-06	0.000216	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—HRAS—thyroid cancer	8.59e-06	0.000215	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—TPR—thyroid cancer	8.53e-06	0.000213	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—TP53—thyroid cancer	8.51e-06	0.000213	CbGpPWpGaD
Vismodegib—ALB—Metabolism—TPR—thyroid cancer	8.48e-06	0.000212	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PRKAR1A—thyroid cancer	8.39e-06	0.00021	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	8.36e-06	0.000209	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PRKAR1A—thyroid cancer	8.35e-06	0.000209	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—HRAS—thyroid cancer	8.14e-06	0.000204	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—HPGD—thyroid cancer	7.97e-06	0.000199	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—TPR—thyroid cancer	7.62e-06	0.00019	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	7.61e-06	0.00019	CbGpPWpGaD
Vismodegib—SHH—Signaling Pathways—AKT1—thyroid cancer	7.58e-06	0.00019	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	7.56e-06	0.000189	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PRKAR1A—thyroid cancer	7.49e-06	0.000187	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—TPR—thyroid cancer	7.43e-06	0.000186	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	7.43e-06	0.000186	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PRKAR1A—thyroid cancer	7.31e-06	0.000183	CbGpPWpGaD
Vismodegib—SMO—Signaling Pathways—AKT1—thyroid cancer	7.19e-06	0.00018	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—TPR—thyroid cancer	6.94e-06	0.000174	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	6.83e-06	0.000171	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	6.79e-06	0.00017	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—SLC5A5—thyroid cancer	6.39e-06	0.00016	CbGpPWpGaD
Vismodegib—ALB—Platelet activation, signaling and aggregation—AKT1—thyroid cancer	6.37e-06	0.000159	CbGpPWpGaD
Vismodegib—ALB—Metabolism—SLC5A5—thyroid cancer	6.35e-06	0.000159	CbGpPWpGaD
Vismodegib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	6.28e-06	0.000157	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	6.19e-06	0.000155	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	5.98e-06	0.00015	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	5.95e-06	0.000149	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—SLC5A5—thyroid cancer	5.7e-06	0.000143	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—SLC5A5—thyroid cancer	5.56e-06	0.000139	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PPARG—thyroid cancer	5.46e-06	0.000137	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—RXRA—thyroid cancer	5.37e-06	0.000134	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	5.34e-06	0.000134	CbGpPWpGaD
Vismodegib—ALB—Metabolism—RXRA—thyroid cancer	5.34e-06	0.000133	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	5.22e-06	0.000131	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—SLC5A5—thyroid cancer	5.2e-06	0.00013	CbGpPWpGaD
Vismodegib—ALB—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	5.19e-06	0.00013	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—NRAS—thyroid cancer	5.09e-06	0.000127	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	4.87e-06	0.000122	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—RXRA—thyroid cancer	4.79e-06	0.00012	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—RXRA—thyroid cancer	4.67e-06	0.000117	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	4.66e-06	0.000117	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—TPR—thyroid cancer	4.58e-06	0.000115	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	4.51e-06	0.000113	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—KRAS—thyroid cancer	4.38e-06	0.000109	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—RXRA—thyroid cancer	4.37e-06	0.000109	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PTGS2—thyroid cancer	4.29e-06	0.000107	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	4.25e-06	0.000106	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—TP53—thyroid cancer	3.89e-06	9.73e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—PTEN—thyroid cancer	3.75e-06	9.37e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—HRAS—thyroid cancer	3.72e-06	9.31e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—SLC5A5—thyroid cancer	3.43e-06	8.57e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PPARG—thyroid cancer	3.39e-06	8.47e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PPARG—thyroid cancer	3.37e-06	8.43e-05	CbGpPWpGaD
Vismodegib—ALB—Hemostasis—AKT1—thyroid cancer	3.29e-06	8.22e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PPARG—thyroid cancer	3.02e-06	7.56e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PPARG—thyroid cancer	2.95e-06	7.38e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—RXRA—thyroid cancer	2.88e-06	7.2e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PPARG—thyroid cancer	2.76e-06	6.9e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PTGS2—thyroid cancer	2.67e-06	6.67e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PTGS2—thyroid cancer	2.65e-06	6.63e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PTGS2—thyroid cancer	2.38e-06	5.95e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—PTEN—thyroid cancer	2.32e-06	5.81e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PTGS2—thyroid cancer	2.32e-06	5.81e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—PTEN—thyroid cancer	2.31e-06	5.78e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PTGS2—thyroid cancer	2.17e-06	5.43e-05	CbGpPWpGaD
Vismodegib—ABCG2—Metabolism—AKT1—thyroid cancer	2.16e-06	5.4e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—PTEN—thyroid cancer	2.07e-06	5.19e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—PTEN—thyroid cancer	2.02e-06	5.06e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—PTEN—thyroid cancer	1.89e-06	4.73e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PPARG—thyroid cancer	1.82e-06	4.55e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PTGS2—thyroid cancer	1.43e-06	3.58e-05	CbGpPWpGaD
Vismodegib—CYP2C8—Metabolism—AKT1—thyroid cancer	1.34e-06	3.35e-05	CbGpPWpGaD
Vismodegib—ALB—Metabolism—AKT1—thyroid cancer	1.33e-06	3.33e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—PTEN—thyroid cancer	1.25e-06	3.12e-05	CbGpPWpGaD
Vismodegib—CYP2C19—Metabolism—AKT1—thyroid cancer	1.2e-06	2.99e-05	CbGpPWpGaD
Vismodegib—ABCB1—Metabolism—AKT1—thyroid cancer	1.17e-06	2.92e-05	CbGpPWpGaD
Vismodegib—CYP2C9—Metabolism—AKT1—thyroid cancer	1.09e-06	2.73e-05	CbGpPWpGaD
Vismodegib—CYP3A4—Metabolism—AKT1—thyroid cancer	7.19e-07	1.8e-05	CbGpPWpGaD
